Biosynex Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Biosynex ha un patrimonio netto totale di €103.2M e un debito totale di €61.5M, che porta il suo rapporto debito/patrimonio netto a 59.6%. Le sue attività totali e le sue passività totali sono rispettivamente €208.8M e €105.5M.

Informazioni chiave

59.6%

Rapporto debito/patrimonio netto

€61.51m

Debito

Indice di copertura degli interessi	n/a
Contanti	€10.74m
Patrimonio netto	€103.21m
Totale passività	€105.54m
Totale attività	€208.75m

Aggiornamenti recenti sulla salute finanziaria

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Jun 23

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Dec 19

Recent updates

Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet

Oct 30

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Aug 16

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

Jun 29

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Mar 12

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

Jan 20

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

May 05

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Dec 01

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { ALBIO di €72.4M ) non coprono le sue passività a breve termine ( €85.8M ).

Passività a lungo termine: Le attività a breve termine di ALBIO ( €72.4M ) superano le sue passività a lungo termine ( €19.7M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 49.2% ) di ALBIO è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di ALBIO è aumentato da 14.6% a 59.6% negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di ALBIO è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di ALBIO siano ben coperti dall'EBIT.

Biosynex Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Recent updates

New major risk - Financial position

Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

Investor sentiment deteriorates as stock falls 22%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

Investor sentiment deteriorated over the past week

New 90-day high: €20.60

Investor sentiment improved over the past week

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: €19.90

First half earnings released

New 90-day high: €13.50

New 90-day high: €12.50

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane